Macromolecular target prediction by self-organizing feature maps

Expert Opinion on Drug Discovery

Volumn 12, Issue 3, 2017, Pages 271-277

  Schneider, Gisbert ^a   Schneider, Petra ^a,b  

^a ETH ZURICH   (Switzerland)

^b InSilicom LLC   (Switzerland)

Author keywords

Chemical biology; deep learning; drug design; machine learning; medicinal chemistry; neural network; off target; phenotypic screening; polypharmacology

Indexed keywords

ARTIFICIAL NEURAL NETWORK; CHEMICAL DATABASE; CHEMICAL STRUCTURE; DRUG DESIGN; DRUG REPOSITIONING; DRUG SCREENING; IN VITRO STUDY; MACHINE LEARNING; MACROMOLECULE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; REVIEW; SELF ORGANIZING MAP; ALGORITHM; COMPUTER SIMULATION; DRUG DEVELOPMENT; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ALGORITHMS; COMPUTER SIMULATION; DRUG DESIGN; DRUG DISCOVERY; DRUG REPOSITIONING; HUMANS; MACROMOLECULAR SUBSTANCES; MOLECULAR TARGETED THERAPY; NEURAL NETWORKS (COMPUTER);

EID: 85013195087     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2017.1274727     Document Type: Review

References (63)

1. Bajorath J., Computational approaches in chemogenomics and chemical biology:current and future impact on drug discovery. Expert Opin Drug Discov. 2008;3:1371–1376.
2. Reker D, Rodrigues T, Schneider P, et al. Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus. Proc Natl Acad Sci USA. 2014;111:4067–4072.•• A full technical description of the consensus SOM method.
3. Wagner BK, Schreiber SL. The power of sophisticated phenotypic screening and modern mechanism-of-action methods. Cell Chem Biol. 2016;23:3–9.
4. Jung HJ, Kwon HJ. Target deconvolution of bioactive small molecules:the heart of chemical biology and drug discovery. Arch Pharm Res. 2015;38:1627–1641.
5. Azad MA, Wright GD. Determining the mode of action of bioactive compounds. Bioorg Med Chem. 2012;20:1929–1939.
6. Katsila T, Spyroulias GA, Patrinos GP, et al. Computational approaches in target identification and drug discovery. Comput Struct Biotechnol J. 2016;14:177–184.
7. Lima AN, Philot EA, Trossini GH, et al. Use of machine learning approaches for novel drug discovery. Expert Opin Drug Discov. 2016;11:225–239.
8. Cichonska A, Rousu J, Aittokallio T. Identification of drug candidates and repurposing opportunities through compound-target interaction networks. Expert Opin Drug Discov. 2015;10:1333–1345.
9. Sliwoski G, Kothiwale S, Meiler J, et al. Computational methods in drug discovery. Pharmacol Rev. 2013;66:334–395.
10. Cleves AN, Jain AN. Robust ligand-based modeling of the biological targets of known drugs. J Med Chem. 2006;49:2921–2938.
11. Keiser MJ, Roth BL, Armbruster BN, et al. Relating protein pharmacology by ligand chemistry. Nat Biotech. 2007;25:197–206.• A seminal paper on substructure-fingerprint-based target prediction.
12. Ain QU, Aleksandrova A, Roessler FD, et al. Machine-learning scoring functions to improve structure-based binding affinity prediction and virtual screening. Wiley Interdiscip Rev Comput Mol Sci. 2015;5:405–424.•• A comprehensive introduction to machine learning methods for virtual screening.
13. Koutsoukas A, Simms B, Kirchmair J, et al. From in silico target prediction to multi-target drug design:current databases, methods and applications. J Proteomics. 2011;74:2554–2574.
14. Bieler M, Reutlinger M, Rodrigues T, et al. Designing multi-target compound libraries with Gaussian process models. Mol Inf. 2016;35:192–198.
15. Rodrigues T, Hauser N, Reker D, et al. Multidimensional de novo design reveals 5-HT2B receptor-selective ligands. Angew Chem Int Ed. 2015;54:1551–1555.
16. Besnard J, Ruda GF, Setola V, et al. Automated design of ligands to polypharmacological profiles. Nature. 2012;492:215–220.•• A seminal paper on multi-objective hit-to-lead optimization.
17. Reker D, Perna AM, Rodrigues T, et al. Revealing the macromolecular targets of complex natural products. Nat Chem. 2014;6:1072–1078.•• Full-fledged application of SOMs to natural product de-orphaning.
18. Schneider G, Reker D, Chen T, et al. De-orphaning the macromolecular targets of the natural anticancer compound doliculide. Angew Chem Int Ed. 2016;55:12408–12411.
19. Rodrigues T, Reker D, Kunze J, et al. Revealing the macromolecular targets of fragment-like natural products. Angew Chem Int Ed. 2015;54:10662–10666.
20. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521:436–444.•• A comprehensive introduction to deep neural networks.
21. Gawehn E, Hiss JA, Schneider G. Deep learning in drug discovery. Mol Inf. 2016;35:3–14.
22. Ekins S. The next era:deep learning in pharmaceutical research. Pharm Res. 2016;33:2594–2603.• A timely and critical review of the field.
23. Gasteiger J, Zupan J. Neural networks in chemistry. Angew Chem Int Ed. 1993;32:503–527.
24. Kohonen T. Self-organized formation of topologically correct feature maps. Biol Cybern. 1982;43:59–69.
25. Schneider P, Tanrikulu Y, Schneider G. Self-organizing maps in drug discovery:compound library design, scaffold-hopping, repurposing. Curr Med Chem. 2009;16:258–266.
26. Haddad I, Hiller K, Frimmersdorf E, et al. An emergent self-organizing map based analysis pipeline for comparative metabolome studies. In Silico Biol. 2009;9:163–178.
27. González-Díaz H1, Arrasate S, Sotomayor N, et al. MIANN models in medicinal, physical and organic chemistry. Curr Top Med Chem. 2013;13:619–641.
28. Vanhaelen Q, Mamoshina P, Aliper AM, et al. Design of efficient computational workflows for in silico drug repurposing. Drug Discov Today. 2016. DOI:10.1016/j.drudis.2016.09.019
29. Schneider G, Wrede P. Artificial neural networks for computer-based molecular design. Prog Biophys Mol Biol. 1998;70:175–222.
30. Baskin II, Winkler D, Tetko IV. A renaissance of neural networks in drug discovery. Expert Opin Drug Discov. 2016;11:785–795.
31. Pastur-Romay LA, Cedrón F, Pazos A, et al. Deep artificial neural networks and neuromorphic chips for big data analysis:pharmaceutical and bioinformatics applications. Int J Mol Sci. 2016;17:1313.
32. Alaimo S, Giugno R, Pulvirenti A. Recommendation techniques for drug-target interaction prediction and drug repurposing. Meth Mol Biol. 2016;1415:441–462.
33. Zhang R, Li J, Lu J, et al. Using deep learning for compound selectivity prediction. Curr Comput Aided-Drug Des. 2016;12:5–14.
34. Hamanaka M, Taneishi K, Iwata H, et al. CGBVS-DNN:prediction of compound-protein interactions based on deep learning. Mol Inf. 2017;36. DOI:10.1002/minf.201600045
35. Tian K, Shao M, Wang Y, et al. Boosting compound-protein interaction prediction by deep learning. Methods. 2016;110:64–72.
36. Romero-Durán FJ, Alonso N, Yañez M, et al. Brain-inspired cheminformatics of drug-target brain interactome, synthesis, and assay of TVP1022 derivatives. Neuropharmacology. 2016;103:270–278.
37. Bajorath J, Overington J, Jenkins JL, et al. Drug discovery and development in the era of big data. Future Med Chem. 2016;8:1807–1813.
38. Kim RS, Goossens N, Hoshida Y. Use of big data in drug development for precision medicine. Expert Rev Precis Med Drug Dev. 2016;1:245–253.
39. Leyens L, Reumann M, Malats N, et al. Use of big data for drug development and for public and personal health and care. Genet Epidemiol. 2017;41:51–60.
40. Mathea M, Klingspohn W, Baumann K. Chemoinformatic classification methods and their applicability domain. Mol Inf. 2016;35:160–180.•• An authoritative review of applicability domains.
41. Schmuker M, Schneider G. Processing and classification of chemical data inspired by insect olfaction. Proc Natl Acad Sci USA. 2007;104:20285–20289.
42. Schneider G, Tanrikulu Y, Schneider P. Self-organizing molecular fingerprints:a ligand-based view on drug-like chemical space and off-target prediction. Future Med Chem. 2009;1:213–218.
43. Schneider P, Müller AT, Gabernet G, et al. Hybrid network model for “deep learning” of chemical data:application to antimicrobial peptides. Mol Inf. 2017;36. DOI:10.1002/minf.201600011
44. Liu W, Johnson DE. Clustering and its application in multi-target prediction. Curr Opin Drug Discov Devel. 2009;12:98–107.
45. Tan L, Bajorath J. Utilizing target-ligand interaction information in fingerprint searching for ligands of related targets. Chem Biol Drug Des. 2009;74:25–32.
46. Ding H, Takigawa I, Mamitsuka H, et al. Similarity-based machine learning methods for predicting drug-target interactions:a brief review. Brief Bioinform. 2014;15:734–747.
47. Sawada R, Kotera M, Yamanishi Y. Benchmarking a wide range of chemical descriptors for drug-target interaction prediction using a chemogenomic approach. Mol Inf. 2014;33:719–731.
48. Givehchi A, Schneider G. Multi-space classification for predicting GPCR-ligands. Mol Divers. 2005;9:371–383.
49. Reutlinger M, Schneider G. Nonlinear dimensionality reduction and mapping of compound libraries for drug discovery. J Mol Graph Model. 2012;34:108–117.
50. Paolini GV, Shapland RHB, Van Hoorn WP. Global mapping of pharmacological space. Nat Biotechnol. 2006;24:805–815.
51. Schneider P, Schneider G. Collection of bioactive reference compounds for focused library design. QSAR Comb Sci. 2003;22:713–718.
52. Noeske T, Sasse BC, Stark H, et al. Predicting compound selectivity by self-organizing maps:cross-activities of metabotropic glutamate receptor antagonists. Chem Med Chem. 2006;1:1066–1068.
53. Papadatos G, Gaulton A, Hersey A, et al. Activity, assay and target data curation and quality in the ChEMBL database. J Comput Aided Mol Des. 2015;29:885–896.
54. Kim S, Thiessen PA, Bolton EE, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44:D1202–13.
55. Richter L, Ecker GF. Medicinal chemistry in the era of big data. Drug Discov Today Technol. 2015;14:37–41.• A comprehensive introduction to the opportunities and challenges of big data for drug discovery.
56. Williams AJ, Harland L, Groth P, et al. Open PHACTS:semantic interoperability for drug discovery. Drug Discov Today. 2012;17:1188–1198.
57. Chen B, Butte AJ. Leveraging big data to transform target selection and drug discovery. Clin Pharmacol Ther. 2016;99:285–297.
58. Schneider G, Hartenfeller M, Reutlinger M, et al. Voyages to the (un)known:adaptive design of bioactive compounds. Trends Biotechnol. 2009;27:18–26.• An overview of SOMs for molecular design and chemical space analysis.
59. Seiffer U, Jain LC. Self-organizing neural networks. Berlin:Springer-Verlag; 2002.
60. Bishop CM, Svensen M, Williams CKI. GTM:the generative topographic mapping. Neural Comput. 1998;10:215–234.
61. Gaspar HA, Marcou G, Horvath D, et al. Generative topographic mapping-based classification models and their applicability domain:application to the Biopharmaceutics Drug Disposition Classification System (BDDCS). J Chem Inf Model. 2013;53:3318–3325.
62. Miyao T, Reker D, Schneider P, et al. Chemography of natural product space. Planta Med. 2015;81:429–435.
63. Gaspar HA, Baskin II, Marcou G, et al. Stargate GTM:bridging descriptor and activity spaces. J Chem Inf Model. 2015;55:2403–2410.• A full technical description of generative topographic mapping for target prediction.